Literature DB >> 25896720

Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice.

Nan Zhang1, Yunxia Lu, Xinru Shen, Yingying Bao, Jingjing Cheng, Li Chen, Bao Li, Qiu Zhang.   

Abstract

Fenofibrate is widely used in clinical practice, but its influence on chronic endoplasmic reticulum (ER) stress induced by feeding a high-calorie and high-cholesterol diet (HCD) has still not been studied. We thus investigated its effects on the liver of the nonalcoholic fatty liver disease (NAFLD) mouse model. Male C57BL/6 mice fed an HCD for 3 months were treated with fenofibrate (HCD + FF, 40 mg/kg, once daily) via gavage for 4 weeks. Insulin sensitivity, serum lipid and inflammatory cytokines were measured. Liver tissues were procured for histological examination as well as analysis of hepatic triglyceride levels, distribution of inflammatory cytokines and genes involved in ER stress. Our results showed that chronic feeding of an HCD successfully induced an NAFLD model accompanied by inflammatory activation, apoptosis and severe ER stress in the liver. Fenofibrate administration significantly improved symptoms of NAFLD and decreased apoptosis, expression of inflammatory cytokines and genes involved in ER stress, such as inositol-requiring enzyme 1α (IRE1α), X-box binding protein 1 (XBP1) and JNK phosphorylation. Thus, our study suggests that fenofibrate protected against inflammatory injury and apoptosis, maybe alleviating ER stress through the IRE1α-XBP1-JNK pathway in the liver of NAFLD mice.
© 2015 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25896720     DOI: 10.1159/000380952

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  11 in total

Review 1.  Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.

Authors:  Amanda Karolina Soares Silva; Christina Alves Peixoto
Journal:  Cell Mol Life Sci       Date:  2018-05-22       Impact factor: 9.261

Review 2.  PPARs and nonalcoholic fatty liver disease.

Authors:  Kim H H Liss; Brian N Finck
Journal:  Biochimie       Date:  2016-12-02       Impact factor: 4.079

Review 3.  Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.

Authors:  Chanbin Lee; Jieun Kim; Youngmi Jung
Journal:  Cells       Date:  2019-10-15       Impact factor: 6.600

4.  Effect of Different Exercise Intensities on Hepatocyte Apoptosis in HFD-Induced NAFLD in Rats: The Possible Role of Endoplasmic Reticulum Stress through the Regulation of the IRE1/JNK and eIF2α/CHOP Signal Pathways.

Authors:  Ling Ruan; Fanghui Li; Shoubang Li; Mingjun Zhang; Feng Wang; Xianli Lv; Qin Liu
Journal:  Oxid Med Cell Longev       Date:  2021-03-15       Impact factor: 6.543

Review 5.  Is there a role of lipid-lowering therapies in the management of fatty liver disease?

Authors:  Ismini Tzanaki; Aris P Agouridis; Michael S Kostapanos
Journal:  World J Hepatol       Date:  2022-01-27

6.  PharmOmics: A species- and tissue-specific drug signature database and gene-network-based drug repositioning tool.

Authors:  Yen-Wei Chen; Graciel Diamante; Jessica Ding; Thien Xuan Nghiem; Jessica Yang; Sung-Min Ha; Peter Cohn; Douglas Arneson; Montgomery Blencowe; Jennifer Garcia; Nima Zaghari; Paul Patel; Xia Yang
Journal:  iScience       Date:  2022-03-10

Review 7.  Cell-Type Resolved Insights into the Cis-Regulatory Genome of NAFLD.

Authors:  Trine V Dam; Nicolaj I Toft; Lars Grøntved
Journal:  Cells       Date:  2022-03-03       Impact factor: 6.600

8.  Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice.

Authors:  Dan Zhang; Shanzhuang Niu; Yicheng Ma; Hang Chen; Yu Wen; Mingke Li; Bo Zhou; Yi Deng; Chunjing Shi; Guangyu Pu; Meng Yang; Xianmei Wang; Chenggang Zou; Yuanli Chen; Lanqing Ma
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

Review 9.  Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases.

Authors:  Tae Woo Jung; Kyung Mook Choi
Journal:  Int J Mol Sci       Date:  2016-02-01       Impact factor: 5.923

10.  Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.

Authors:  Shahar Azar; Shiran Udi; Adi Drori; Rivka Hadar; Alina Nemirovski; Kiran V Vemuri; Maya Miller; Dana Sherill-Rofe; Yhara Arad; Devorah Gur-Wahnon; Xiaoling Li; Alexandros Makriyannis; Danny Ben-Zvi; Yuval Tabach; Iddo Z Ben-Dov; Joseph Tam
Journal:  Mol Metab       Date:  2020-09-26       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.